GENENTECH WILL COLLECT MORE PULMONARY FUNCTION DATA ON CYSTIC FIBROSIS PATIENTS, BOTH THOSE TREATED WITH PULMOZYME AND UNTREATED AS PART OF PHASE IV WORK
Genentech will collect long-term epidemiology data on a large group of cystic fibrosis patients to develop more information about changes in pulmonary function and parenteral antibiotic use over an extended period of time. The data collection is part of a five-point plan for follow-up research in the wake of the approval of Pulmozyme agreed to by Genentech in discussions with FDA and set forth in the final approval letter issued by the agency on Dec. 30.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth